The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMP.L Regulatory News (AMP)

  • There is currently no data for AMP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Amphion Innovations plc Partner Company Supertron Acquires Spin Systems

13 Nov 2006 14:58

Amphion Innovations plc ("Amphion"), a developer of life sciencesand technology businesses, announces today that one of its PartnerCompanies, Supertron Technologies ("Supertron"), a developer of highperformance clinical and preclinical imaging products for magneticresonance imaging (MRI), has acquired Spin Systems, an Australia basedmanufacturer of MRI coils and other imaging accessories. Following theacquisition, the enlarged company will change its name to m2m ImagingCorporation ("m2m") to encapsulate the broad spectrum of"molecule-to-man" imaging products the new combined company isdeveloping. £ Spin Systems was acquired by Superton for 313,878 Series CPreferred Shares valued at $5.00 per share and $752,284 in cash. Thetotal consideration of the acquisition was $2,322,000. £ Supertron Chief Executive Officer C. Richard Hullihen will serveas the CEO of the combined company. Amphion will be the largeststrategic investor in m2m with a 23.5% percent ownership interest. Thepost acquisition value for m2m is $20m based on the offering price ofthe Series C Round, closed in July 2006. £ m2m will combine Spin Systems' well-established portfolio of MRIcoils and accessories with Supertron's cryogenic coil technology. Thecryogenic coil has been shown to dramatically improve the performanceof the MRI scanner, producing significantly clearer images in lesstime. £ Richard C. E. Morgan, Amphion's Chief Executive Officer, said: £ "m2m's evolution demonstrates the strength of Amphion's companybuilding model. Since Supertron became one of Amphion's PartnerCompanies, we have developed it rapidly from a University start-upinto an established, revenue producing company, with industry leadingpartners, strong technology and world class management. £ "The cryogenic coils have the potential to provide doctors andclinicians with much needed superior imaging for earlier diseasedetection and faster drug development. m2m's products greatly enhanceMRI imaging by reducing scan time, greatly lowering the cost andproducing significantly clearer images." £ About Amphion Innovations plc £ Amphion Innovations plc (AMP) is listed on the AIM of the LondonStock Exchange. Amphion's business activities are the formation,financing, management and development of life sciences and technologycompanies, working in partnership with corporations, governments,universities and entrepreneurs seeking to commercialize theirintellectual property. £ Website: www.amphionplc.com £ About m2m Imaging Corp. £ m2m Imaging is a market leading developer and manufacturer ofconventional and cryogenic preclinical and clinical MRI coils andimaging accessories. Our gateway technology MRI coils havedemonstrated capability of significantly increasing speed andresolution of the MRI scanner for imaging molecules to man. m2m'scoils have been demonstrated at leading medical institutions such asBrigham & Women's Hospital of Harvard Medical School. £ Website: www.m2mimaging.com Copyright Business Wire 2006
Date   Source Headline
31st Dec 20191:15 pmRNSAmphion Innovations
31st Dec 201912:36 pmRNSCancellation of trading on AIM
20th Nov 20197:00 amRNSDirectors' Dealings and Business Update
18th Oct 20197:00 amRNSSettlement of loan facility
11th Oct 20197:01 amRNSPolarean notes statement from Amphion Innovations
11th Oct 20197:00 amRNSSale of Partner Company Shares
3rd Oct 20197:00 amRNSSale of Partner Company Shares
25th Sep 20197:00 amRNSAmended Terms on Loan Facility
10th Sep 20194:56 pmRNSSale of Partner Company Shares
9th Aug 20194:14 pmRNSStatement on Amphion Innovations
9th Aug 20194:14 pmRNSDirectorate Change
9th Aug 20193:51 pmRNSSale of Partner Company Shares
1st Jul 20197:30 amRNSSuspension - Amphion Innovations Plc
27th Jun 20193:00 pmRNSAnnual Report and Accounts Update
14th Jun 20199:04 amRNSHolding(s) in Company
12th Jun 20197:00 amRNSLoan facility update
31st May 201910:28 amRNSHolding(s) in Company
20th May 20196:14 pmRNSHolding(s) in Company
1st Apr 20194:40 pmRNSSecond Price Monitoring Extn
1st Apr 20194:35 pmRNSPrice Monitoring Extension
1st Apr 20197:00 amRNSUpdate on Loan Facility
20th Mar 20197:00 amRNSHolding(s) in Company
19th Mar 20192:33 pmRNSSale of Partner Company Shares
18th Mar 20192:00 pmRNSPrice Monitoring Extension
15th Mar 20197:01 amRNSHolding(s) in Company
15th Mar 20197:00 amRNSSale of Partner Company Shares
11th Mar 20194:41 pmRNSAmended Terms on Loan Facility
26th Feb 20197:00 amRNSConvertible Promissory Note Extended
14th Feb 20198:00 amRNSStatement re. Motif Bio plc
7th Feb 20199:40 amRNSStmnt re Share Price Movement
1st Feb 20197:00 amRNSAppointment of Joint Broker
21st Jan 20197:00 amRNSWellGen Finalises License Agreement
11th Dec 20187:05 amRNSInvestment in Polarean & Loan Facility Repayment
16th Oct 20187:00 amRNSExtended Repayment and Draw Down on Loan Facility
28th Sep 20187:00 amRNSHalf-year Report
5th Sep 20187:00 amRNSBoard Change
23rd Aug 20183:20 pmRNSPolarean update
21st Aug 20187:15 amRNSMotif Bio notes statement from Amphion Innovations
21st Aug 20187:00 amRNSSale of Partner Company Shares
1st Aug 20184:47 pmRNSResult of AGM
29th Jun 20187:00 amRNSDirectorate Change
26th Jun 20187:00 amRNSFinal Results
23rd May 20187:00 amRNSMotif Bio notes statement from Amphion Innovations
23rd May 20187:00 amRNSSale of Partner Company Shares
20th Apr 20187:00 amRNSDirectorate Change
29th Mar 20187:00 amRNSAIM Admission & First Day of Dealings
29th Mar 20187:00 amRNSUpdate on Polarean Imaging IPO
26th Mar 20187:31 amRNSUpdate on Polarean Imaging proposed AIM IPO
2nd Mar 20187:00 amRNSConvertible promissory note extended to December
10th Jan 20185:09 pmRNSDirector dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.